Dataset
All samples in this dataset are included in the "DIAMANTE (European) T2D GWAS" dataset.
Publications
Sequence data and association statistics from 12,940 type 2 diabetes cases and controls.
Flannick J, Fuchsberger C, Mahajan A, et al.
Sci Data. 2017 Dec 19;4:170179. doi: 10.1038/sdata.2017.179
The genetic architecture of type 2 diabetes.
Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, et al.
Nature 2016 Aug 4;536(7614):41-7. doi: 10.1038/nature18642
Dataset phenotypes
Dataset subjects
| Cases |
Controls |
Cohort |
Ancestry |
| 132 |
455 |
MT. SINAI BioMe Biobank Platform (BioMe (Affy))
| Case selection criteria |
Control selection criteria |
- From longitudinal EMR: random glucose ≥ 200 mg/dl ever, or physician-entered diagnosis (≥2 occurrences on 2 separate days), or T2D medication (≥2 occurrences on 2 separate days)
- Age ≥ 25 years
|
- Age ≥25 years
- Not having T2D
- All available fasting glucose measurements <100 mg/dl
|
|
European |
| 255 |
1647 |
MT. SINAI BioMe Biobank Platform (BioMe (Illumina))
| Case selection criteria |
Control selection criteria |
- From longitudinal EMR: random glucose ≥ 200 mg/dl ever, or physician-entered diagnosis (≥2 occurrences on 2 separate days), or T2D medication (≥2 occurrences on 2 separate days)
- Age ≥ 25 years
|
- Age ≥25 years
- Not having T2D
- All available fasting glucose measurements <100 mg/dl
|
|
European |
| 677 |
697 |
Diabetes Gene Discovery Group (DGDG)
| Case selection criteria |
Control selection criteria |
- 1997 American Diabetes Association (ADA) criteria
- Family history of diabetes in first-degree relatives
- BMI <30 kg/m2
- Cases with age of diagnosis <45 years were screened for known MODY mutations
- Cases from the Corbeil-Essonnes Hospital tested for fasting C-peptide levels; if fasting C- peptide <0.4 mg/l, subjects tested for anti-GAD antibodies; those with anti-GAD antibodies >10U/ml excluded
- 29% of cases from UMR8090 CNRS tested for anti-islet antibodies and/or anti-insulin antibodies; positive cases excluded
|
- Age at examination >45 years
- Normal fasting glucose according to 1997 ADA criteria: FG <5.7 mmol/l - BMI <27 kg/m2
|
|
European |
| 899 |
1057 |
Diabetes Genetics Initiative (DGI)
| Case selection criteria |
Control selection criteria |
- WHO (1999) criteria with fasting glucose ≥7.0 mmol/l or 2-hour glucose ≥11.1 mmol/l during an oral glucose tolerance test
- Age of diagnosis >35 years
- Anti-GAD antibodies <32 IU/ml in the Finnish samples and <1.3 anti-GAD relative units in the Swedish samples
|
- No first-degree relatives with T2D
|
|
European |
| 389 |
6013 |
Estonian Genome Center, University of Tartu (EGCUT- OMNI)
| Case selection criteria |
Control selection criteria |
- Standardized health examination together with questionnaires on health-related topics as described in WHO ICD-10. Data are regularly updated through linkage to national databases and registries.
|
- Random subset of the Estonian population
|
|
European |
| 80 |
1768 |
Estonian Genome Center, University of Tartu (EGCUT- 370)
| Case selection criteria |
Control selection criteria |
- Standardized health examination together with questionnaires on health-related topics as described in WHO ICD-10. Data are regularly updated through linkage to national databases and registries.
|
- Random subset of the Estonian population
|
|
European |
| 673 |
7660 |
Framingham Heart Study (FHS)
| Case selection criteria |
Control selection criteria |
- Gen 1 cohort: casual glucose ≥200 mg/dl or taking diabetes medication at any examination
- Gen 2 cohort (offspring): FG≥126 mg/dl or diabetes treatment at any examination
- Gen 3 cohort: fasting glucose ≥126 mg/dl or diabetes treatment at examination
|
- Fasting glucose <126 mg/dl and no T2D medication at the most recent study visit
|
|
European |
| 1060 |
1090 |
Finland-United States Investigation of NIDDM Genetics (FUSION) Study
| Case selection criteria |
Control selection criteria |
- WHO 1999 criteria of FG≥7.0 mmol/l or 2-hour plasma glucose ≥11.1 mmol/l or reported diabetes medication use or based on medical record review
- No known or probable type 1 diabetes among first degree relatives
- excluded if insulin treatment initiated within 10 years of disease diagnosis, detectable levels of anti-GAD antibodies and fasting C-peptide ≤0.30 nmol/l
- excluded if insulin treatment initiated within 4 years of diagnosis and fasting C-peptide ≤0.30 nmol/l
|
- NGT as defined by WHO 1999 criteria
|
|
European |
| 4624 |
4668 |
InterAct
| Case selection criteria |
Control selection criteria |
- Self-report (self-reported history of T2D, doctor-diagnosed T2D, diabetes drug use) and linkage to primary care registers, secondary care registers, medication use (drug registers), hospital admissions, and mortality data, using information from any follow-up visit or external evidence with a date later than the baseline visit
- In Sweden, cases ascertained via local and national diabetes and pharmaceutical registers
- Centers outside Sweden required evidence of T2D from ≥2 independent sources, including individual medical records review at some centers
|
|
|
European |
| 993 |
2985 |
KORAgen Study Helmholtz zentrum München
| Case selection criteria |
Control selection criteria |
- Self-report in personal interview validated by a questionnaire mailed to the treating physician and/or by medical chart review
|
- Non-diabetic by self-report
|
|
European |
| 111 |
838 |
Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS)
| Case selection criteria |
Control selection criteria |
- Fasting blood glucose >6.1 mmol/l or known diabetes
|
|
|
European |
| 166 |
953 |
Uppsala Longitudinal Study of Adult Men (ULSAM)
| Case selection criteria |
Control selection criteria |
- Hospital discharge register-defined diabetes before 2002
|
|
|
European |
| 1586 |
2938 |
Wellcome Trust Case Control Consortium (WTCCC)
| Case selection criteria |
Control selection criteria |
- Current prescribed treatment with oral agents and/or insulin, or, for individuals treated with diet alone, laboratory evidence of hyperglycemia as defined by WHO
- All cases were diagnosed between ages 25 and 75 years
- Absence of first-degree relatives with T1D
- Individuals with other known forms of diabetes were excluded
- ≥ 1 year between diagnosis and institution of regular insulin therapy
- Negative testing for anti-GAD antibodies
|
- Selected without reference to T2D status
- 1958 Birth Cohort controls of self-reported white ethnicity and representative of gender and each geographical region
- UK blood donor controls selected based on sex and geographical region to reproduce the distribution of the samples of the 1958 Birth Cohort
|
|
European |
| Total: 11,645 |
Total: 32,769 |
|
|
Project
Genetics of Type 2 Diabetes (GoT2D) Learn more >
The GoT2D consortium aims to understand the allelic architecture of type 2 diabetes through whole-genome sequencing, high-density SNP genotyping, and imputation. The reference panel based on this work is intended as a comprehensive inventory of low-frequency variants in Europeans, including SNPs, small insertions and deletions, and structural variants.
